BrandWikiReturn

Novo Nordisk

WorldBrand briefing

AI supplement

Original synthesis to sit alongside the encyclopedia article below. Not part of Wikipedia; verify facts on Wikipedia when precision matters.

Novo Nordisk A/S is a leading Danish multinational pharmaceutical corporation focused on chronic disease care, including diabetes, obesity, cardiovascular conditions, and rare disorders like hemophilia. Founded in 1989 via the merger of two pioneering Danish insulin manufacturers, the company is headquartered in Bagsvaerd, Denmark, and operates in more than 80 countries worldwide.

Key moments

  • 1921University of Toronto researchers discover insulin, spurring Danish efforts to mass-produce the diabetes treatment
  • 1923Two predecessor firms, Novo Terapeutisk Laboratorium and Nordisk Insulaboratorium, are established in Denmark
  • 1985Launches the first NovoPen insulin injection pen, revolutionizing at-home diabetes treatment delivery
  • 1989Merger of the two predecessor companies forms Novo Nordisk A/S
  • 2017Introduces semaglutide (brand name Ozempic) for type 2 diabetes, followed by the oral formulation Rybelsus in 2019
  • 2021FDA approves semaglutide (Wegovy) for chronic weight management in adults with obesity or overweight
  • 2023Becomes Europe's most valuable publicly traded company with a market capitalization over $400 billion

Novo Nordisk is a dominant player in the global diabetes and obesity pharmaceutical markets, with its GLP-1 agonist products reshaping the industry in recent years. The company's competitive position is built on strong intellectual property, extensive global distribution, and a robust research pipeline, though it faces growing challenges from rivals and regulatory pressures.

  • Holds a leading share of the global insulin and GLP-1 agonist markets, with semaglutide-based products becoming some of the highest-selling drugs worldwide
  • Key competitors include Eli Lilly (with tirzepatide products Mounjaro and Zepbound) and Sanofi, which offer competing diabetes and obesity treatment lines
  • Benefits from patent protection for its core semaglutide products through the early 2030s, though generic competitors are emerging in key regional markets like China
  • Maintains a strong footprint in North America and Europe, with expanding presence in emerging markets across Asia and Latin America
  • Faces government pricing scrutiny in major markets, as well as supply chain constraints due to surging demand for its obesity treatments

Novo Nordisk has established itself as one of the most trusted and influential brands in the global pharmaceutical industry, with a singular focus on chronic disease care that has built deep loyalty among patients, clinicians, and healthcare systems worldwide. The brand’s association with breakthrough diabetes treatments and more recently, game-changing GLP-1 agonist therapies for obesity, has catapulted its visibility and relevance beyond core medical circles into mainstream public consciousness, cementing its status as an innovation leader in the sector.

The brand benefits from a strong reputation for ethical practice and patient-centricity, rooted in its Danish origins and long history of addressing unmet medical needs. Its sustained investment in research and development, with a pipeline focused on expanding access to chronic disease treatments, supports ongoing brand relevance and differentiation from competitors, even as rivalry in the GLP-1 and diabetes space intensifies.

While regulatory challenges and generic competition on older products create some headwinds, Novo Nordisk’s brand equity remains robust, supported by widespread global distribution and long-standing partnerships with healthcare stakeholders. The brand’s ability to adapt to shifting market demands, including the growing global burden of obesity and diabetes, positions it well to maintain its strength in coming years.

Brand leadership

Score: 90/100

Novo Nordisk holds a clear leading position in the global diabetes care market and dominates the fast-growing GLP-1 agonist segment for obesity treatment, outpacing most competitors in product adoption and clinical credibility. Its brand is widely recognized by clinicians as a gold standard for chronic disease therapies, giving it significant influence over industry trends and global treatment guidelines.

Customer interaction

Score: 82/100

The brand maintains frequent, trusted interactions with both healthcare providers and patient communities, supporting education and access programs for people living with diabetes and obesity. It leverages digital channels and patient advocacy initiatives to build direct connections, though broader public interaction was historically limited compared to consumer-facing brands, even after the rise of its high-demand obesity products.

Brand momentum

Score: 92/100

Driven by the widespread success and popular demand for its GLP-1 products, Novo Nordisk’s brand has seen explosive growth in global awareness and market value in recent years. Its robust pipeline of next-generation chronic disease treatments keeps investor and consumer confidence high, creating strong positive momentum that outpaces most other pharmaceutical brands focused on chronic care.

Brand stability

Score: 88/100

As a well-established multinational with decades of consistent performance in the pharmaceutical sector, Novo Nordisk benefits from strong financial stability and consistent, purpose-aligned brand messaging. It has weathered past patent expirations and regulatory changes without significant erosion of its core brand equity, supported by a diversified product portfolio and loyal stakeholder base.

Brand heritage

Score: 85/100

While the modern Novo Nordisk corporation was formed via merger in 1989, its predecessor companies were pioneering Danish insulin manufacturers dating back to the 1920s, giving it nearly a century of heritage in diabetes care. This long history of innovation and patient care builds deep perceived trust, with the brand’s legacy acting as a major asset rather than a sign of stagnation.

Industry profile

Score: 91/100

Novo Nordisk is one of the most high-profile companies in the global pharmaceutical industry, particularly in the fast-growing chronic disease and weight management segments. Its GLP-1 products have reshaped global industry strategy and drawn significant public and investor attention to the category, making it a benchmark for success in specialty pharmaceutical innovation.

Global brand reach

Score: 83/100

Novo Nordisk operates in more than 80 countries worldwide, with a strong presence in both developed and emerging markets, and a majority of its revenue comes from outside its home region of Europe. While its brand recognition is highest in North America and Europe, it continues to expand access to its products in low- and middle-income markets, steadily increasing its global footprint over time.

AI can support structured reasoning about a brand's underlying value based on public industry data and market position, but any generated estimates are illustrative only and not audited. For a fully verified, audited brand value assessment for Novo Nordisk, contact the World Brand Lab.

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd.[3] Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.[4]

Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices.[5]

Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries.[6] The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[7]

The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017.[8][9][10] In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth.[11] It is a leader in the FTSE4Good Index, and the only European company in the top ten.[12] Novo Nordisk is the largest pharmaceutical company in Denmark.[13] Novo Nordisk's market capitalization exceeded the GDP of Denmark's domestic economy in 2023, and it is the highest valued company in Europe.[14] Net sales in 2024 were US$42.121 billion.

History

1922-1925

In 1922, August Krogh, a professor at the University of Copenhagen, went on a lecture tour to North America after receiving the Nobel Prize in Physiology or Medicine. During this tour, Krogh and his wife Marie visited Toronto where the scientists Frederick Banting, Charles Best and John Macleod had just succeeded in manufacturing active insulin. Krogh received permission to manufacture insulin in the Nordic countries and joined forces with Hans Christian Hagedorn, a physician specialising in diabetes, to start the production of insulin in Denmark. This led to the establishment of Nordisk Insulinlaboratorium company in 1923.[15]

In 1925, brothers Harald and Thorvald Pedersen, who were former employees of Nordisk, formed their own company, Novo Terapeutisk Laboratorium. Novo and Nordisk competed until they merged in 1989 to become Novo Nordisk A/S.[16]

1982–1994

The company established its presence in the United States in 1982 via a joint venture with Squibb Corporation[17] and Canada in 1984.[18]

In 1985, the company introduced the first insulin pen device called Novopen.[19]

In 1989, Novo Industri A/S (Novo Terapeutisk Laboratorium) and Nordisk Gentofte A/S (Nordisk Insulinlaboratorium) merged to become Novo Nordisk A/S, the world's largest producer of insulin with headquarters in Bagsværd, Copenhagen.[20]

In 1991, Novo Nordisk Engineering (now NNE A/S) demerged after working as in-house consultants at Novo Nordisk for years, to provide standard engineering services (end-to-end engineering) to pharma manufacturing companies.[21]

In 1994, Novo Nordisk's existing information technology units was spun out as NNIT A/S. The company was converted into a wholly owned aktieselskab in 2004[22] In March 2015, NNIT was floated on the Nasdaq Nordic.

2000–2018

Novo's enzymes business, Novozymes A/S, was spun-out in 2000.[23]

Novo acquired Xellia for $700 million in 2013.[24]

The same year, Novo Nordisk USA moved into new headquarters offices in Plainsboro Township, New Jersey, by way of extensively renovating abandoned premises. This action served to consolidate several facilities that the company had previously had in Plainsboro.[25]

In 2015, the company announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate.[26]

In January 2018, Reuters reported that Novo had offered to acquire Ablynx for $3.1 billion - having made an unreported offer in mid-December for the company.[27] However, the Ablynx board rejected this offer the same day, explaining that the price undervalued the business.[27] Ultimately Novo lost out to Sanofi who bid $4.8 billion. Later, in the same year, the company announced it would acquire Ziylo for around $800 million.[28]

2020–present

In March 2020, Novo volunteers started testing samples for SARS-CoV-2 with RT-qPCR equipment in the ongoing coronavirus pandemic to increase available test capacity.[29] In June, the business announced it would acquire AstraZeneca's cardiovascular disease-focused spin-off Corvidia Therapeutics for an initial sum of $725 million (up to a performance-related maximum of $2.1 billion).[30] In November, the company announced it would acquire Emisphere Technologies for $1.8 billion, gaining control of a pill-based treatment for diabetes.[31] Novo then announced in December that it would acquire Emisphere Technologies for $1.35 billion.[32]

In November 2021, Novo announced it would acquire Dicerna Pharmaceuticals and its RNAi therapeutics, for $3.3 billion ($38.25 per share).[33]

In September 2022, Novo agreed to acquire Forma Therapeutics for $1.1 billion with the intent to expand its sickle cell disease and rare blood disorders portfolio.[34]

By 2022 the popularity of Novo's Wegovy and Ozempic for weight loss was so great as to significantly increase the growth of the entire economy of Denmark. Two-thirds of Denmark's overall economic growth in 2022 was attributed to the pharmaceutical industry.[35] The company's profits increased by 45% year over year in the first half of 2023. Most of the growth occurred from its weight loss drugs, Wegovy and Ozempic, which accounted for 55% of the company's 2023 revenue.

In August 2023, Novo agreed to acquire the Montreal-headquartered pharmaceutical company, Inversago Pharma for $1 billion[36] and Embark Biotech for up to $500 million.[37] In October 2023, the company announced it would acquire ocedurenone—an experimental drug for uncontrolled hypertension and potentially beneficial in treating cardiovascular and kidney diseases—from KBP Biosciences for $1.3 billion.[38] After a failed clinical trial the following year, Novo Nordisk initiated legal action against KBP alleging that the company misrepresented the drug's effectiveness by concealing unfavorable clinical trial data. Seeking up to $830 million in damages, the Singapore International Commercial Court granted Novo Nordisk's request for a freeze on KBP's assets and those of its founder, Huang Zhenhua.[39][40]

In November 2023, Novo Nordisk announced investment of €2.1 billion in a French production facility to increase the production capacity and manufacturing of its popular anti-obesity medication.[41]

In February 2024, parent company Novo Holdings A/S agreed to acquire Catalent for $16.5billion. On completion, Novo Nordisk said it would acquire three manufacturing facilities from its parent for $11billion to scale up production to meet the massive demand for Wegovy and Ozempic.[42][43]

In March 2024, Novo Nordisk reached a $604 billion market capitalization and became the 12th most valuable company in the world. The company's stock jumped to a record high after early trial data showed positive results for its new experimental weight loss pill amycretin.[44] The company also announced it would acquire Cardior Pharmaceuticals and its cardiovascular disease portfolio for up to $1.1 billion.[45]

As of April 2024, the flow of cash from Novo Nordisk's weight-loss drugs was continuing to solidify its status as the most valuable company in Europe, to the point that economists were worried that Denmark might come down with Dutch disease (that is, a country that does only one thing well and nothing else).[46][47] The company's market capitalization of $570 billion remained larger than the entire economy of Denmark, its $2.3 billion income tax bill for 2023 made it the largest taxpayer in the country, and its rapid growth was driving nearly all of the expansion of Denmark's economy.[46][47] The company had started to move away from its traditional focus on diabetes care towards a more ambitious mission to "defeat serious chronic diseases", and towards that end, hired over 10,000 people in 2023 alone.[48] To effectively manage the rapid expansion of its workforce while maintaining its traditional corporate culture, the Novo Nordisk Way, the company put over 400 senior executives through a leadership development program called NNX, which stands for Novo Nordisk Next.[48]

In May 2024, the company announced it would acquire Austrian fluid management service business, Single Use Support.[49]

In June 2024, the company announced plans to build a new production plant in Clayton, North Carolina, at a cost of $4.1 billion. It will be the company's fourth in the state of North Carolina and used for production of semaglutide products Ozempic and Wegovy.[50] The company also announced plans to acquire three US-based Catalent sites in to increase production supply.[51]

As of October 2024, Novo Nordisk was the second most valuable drug company in the world by market capitalization, second only to its competitor Eli Lilly and Company.[52] By July 2025, Novo Nordisk had fallen to become the fifth most valuable drug company amid rising competition from generic weight loss substitutes. The company named Maziar Mike Doustdar as the new CEO, effective August 7, 2025.[53]

In March 2025, the company announced new plans for a direct-to-consumer offering of its Wegovy weight loss drug. The company established a new pharmacy, called NovoCare, which would charge customers $499 per month for access to the drug, less than half the cost of the drug through other pharmaceutical distribution networks.[54]

In September 2025, Novo Nordisk announced that it would reduce its global workforce by 9,000 people, approximately 9% of its total workforce.[55]

In October 2025, Novo Nordisk acquired Akero Therapeutics for $5.2 billion. Akero Therapeutics is a clinical stage company focusing on the treatment of metabolic dysfunction-associated steatohepatitis (MASH).[56]

In 2026, new obesity GLP-1 pills were launched, with patients getting their hands on them from Danish drugmaker Novo Nordisk.[57]

Products

Novo Nordisk makes the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy.[58] Novo Nordisk is also involved with hemostasis management, growth hormone therapy, and hormone replacement therapy. The company makes several drugs under various brand names, including Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.[1]

Toxicogenomics

Novo Nordisk is involved in government funded collaborative research projects with other industrial and governmental partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[59][60] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of European Federation of Pharmaceutical Industries and Associations and the European Commission.[61]

Research and pipeline

In 2025, Novo Nordisk tested whether semaglutide helped slow progression for Alzheimer’s disease. However, on Nov. 24, 2025, the company announced that the studies failed to find any effect of the drug on cognition and functioning in people with mild cognitive impairment or with dementia.[62]

Novo Nordisk was researching pulmonary delivery systems for diabetic medications, and in the early stages of research into autoimmune and chronic inflammatory diseases, using technologies such as translational immunology and monoclonal antibodies.[63] In September 2014, the company announced a decision to discontinue all research in inflammatory disorders, including the discontinuation of R&D in anti-IL-20 for the treatment of rheumatoid arthritis.[64]

In September 2018, it was reported that the company would lay off 400 administrative staff, laboratory technicians and scientists, in Denmark and China in order to concentrate research and development efforts on “transformational biological and technological innovation”.[65]

Controversies

In 2010, Novo Nordisk breached the code of conduct for Association of the British Pharmaceutical Industry (ABPI), by failing to provide information about side-effects of Victoza and by promoting Victoza prior to being granted market authorisation.[66]

In 2013, Novo Nordisk had to pay back dkk3.6billion to the Danish tax authorities due to transfer mispricing.[67]

In March 2013, a debate emerged in which scientists questioned whether the incretin class of diabetic medications – the class to which Victoza belongs – had an increased risk of side effects in the pancreas such as pancreatitis and pancreatic cancer. It was concluded that data currently available did not confirm these concerns.[68]

In October 2013, batches of NovoMix 30 FlexPen and Penfill insulin were recalled in some European countries as their analysis had shown that a small percentage of the products in these batches did not meet the specifications for insulin strength.[69]

In September 2017, Novo Nordisk agreed to pay $58.7 million to end a United States Department of Justice probe into the lack of FDA disclosure to doctors about the cancer risk for their diabetic drug, Victoza.[70]

In March 2023, Novo Nordisk was suspended from the ABPI for a period of two years, for engaging in misleading marketing practices that amounted to "bribing health professionals with inducement to prescribe".[71] This is only the eighth time in the last 40 years that ABPI sanctioned a member organization.[72] Consequently, the Royal College of General Practitioners[73] and the Royal College of Physicians[74] ended their corporate partnerships as it would be in breach of their ethical guidance. The Novo Nordisk UK General Manager, Pinder Sahota, chose to resign as President of the ABPI prior to the suspension.[72]

In August 2023, one of the first lawsuits was filed alleging that Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro (tirzepatide) caused severe gastrointestinal side effects, including gastroparesis.[75] The lawsuit was brought on behalf of Jaclyn Bjorklund, a Louisiana woman represented by Morgan & Morgan, who alleged that she suffered persistent vomiting and other serious injuries after using the drugs and that the manufacturers failed to adequately warn patients and physicians about the risks.[75]

In September 2023, the law firm Motley Rice filed a lawsuit on behalf of a Pennsylvania woman who had been taking weight-loss drug Wegovy.[76] The lawsuit alleges that the plaintiff experienced severe stomach cramping, vomiting, and nausea requiring hospitalization, and that Novo Nordisk failed to adequately warn patients about the risk of gastroparesis.[76]

In February 2024, the United States Judicial Panel on Multidistrict Litigation ordered that 55 lawsuits pending in federal courts be consolidated into a multidistrict litigation. The majority of the cases were against Novo Nordisk, but some were brought against Eli Lilly. As of August 2024 there were 235 active Ozempic lawsuits. Following the consolidation, the court appointed a plaintiffs’ leadership committee to coordinate the litigation, which included attorneys from the law firms Susen Law Group, Motley Rice, Levin Papantonio, Morgan & Morgan, Pogust Goodhead, and Johnson Becker.[77]

In July 2024, Todd Engel, a Howard County man represented by attorneys from Motley Rice, filed a nine-count complaint in New Jersey state court alleging that Ozempic left him permanently blind.[78] Engel claimed that Novo Nordisk failed to warn doctors or consumers about the risk of non-arteritic anterior ischemic optic neuropathy and accused the company of negligent misrepresentation and defective design.[78]

In 2024 Novo Nordisk drug pricing in the US has been a target of lawmakers, including Senator Bernie Sanders and the Senate committee Health, Education, Labor and Pensions (HELP). The committee investigation found Novo Nordisk's drug Ozempic priced for $969 per month in the US, compared to $155 in Canada and $59 in Germany. Its weight-loss drug Wegovy is priced for $1,349 per month in the US compared to $140 in Germany and $92 in the UK.[79] In July 2024, US President Joe Biden joined Sanders in stating "Novo Nordisk and Eli Lilly must stop ripping off Americans with high drug prices."[80]

In September 2024, Lars Fruergaard Jørgensen, CEO at the time was summoned to testify to the US Senate Health, Education, Labor and Pensions Committee at a hearing in Washington DC. During the hearing Senator Sanders reiterated his issues with the pricing of weight loss drug.[81]

In 2025, the Irish Health Products Regulatory Authority identified several non-compliances relating to advertising rules in educational and training materials in 2021 and 2022. A May 2021 teaching guide did not feature statements on adverse reactions, precautions and contraindications, while materials in November 2021 and April 2022 were unbalanced and promotional in nature, and consideration was not given to the appropriateness of hiring a trainer to carry out consultations with patients during a pilot training course.[82]

That same year, U.S. District Judge Karen Marston issued the first substantive rulings in the multidistrict litigation, dismissing several claims while allowing core allegations - including claims that the manufacturers failed to warn about gastrointestinal risks - to proceed.[83] At that stage, the litigation encompassed more than 2,600 individual lawsuits involving Ozempic, Mounjaro, and related GLP-1 receptor agonist drugs.[83]

Corporate affairs

Finances

For the fiscal year 2024, Novo Nordisk reported earnings of DKK 101 billion (around 14.5 billion USD), with an annual revenue of DKK 290.4 billion (around 42.1 billion USD), an increase of 25% over the previous fiscal cycle.[84][85]

Ownership

Novo Nordisk shares are mostly owned by institutional investors and Novo Holdings A/S. The largest shareholders in 2025 were:[86]

See also

  • Captain Novolin
  • NNIT (formerly Novo Nordisk IT)
  • Novo Nordisk Foundation
  • Novo Nordisk Foundation Center for Protein Research
  • Repaglinide
  • Team Novo Nordisk

External links

References

  1. Annual Report 2024 Novo Nordisk, retrieved February 5, 2025^
  2. Financial report for the period 1 January 2025 to 31 December 2025 Novo Nordisk, February 3, 2026^
  3. Who we are www.novonordisk.com, retrieved 2021-09-28^
  4. Novo Nordisk share and ownership structure retrieved 2023-08-24^
  5. Novo Nordisk sees slower 2020 growth with US insulin prices pressured CNBC, 2020-02-05, retrieved 2020-04-20^
  6. Annual Report 2021 Novo Nordisk, retrieved March 13, 2022^
  7. The Pharmaceutical Industry in Figures - 2008 Edition European Federation of Pharmaceutical Industries and Associations (EFPIA), retrieved 2008-08-25^
  8. 100 Best Companies to Work For 2010: Full list Fortune, 2010^
  9. Fortune 100 Best Companies to Work For® 2017 Great Place To Work®, retrieved 2024-06-26^
  10. Emily Wasserman. Novo Nordisk Named on the 2014 FORTUNE 100 Best Companies to Work For® List for Sixth Consecutive Year Fierce Pharma, January 16, 2024, retrieved June 26, 2024^
  11. Bart King Published 8 years ago About a 2 minute read. Novo Nordisk Ranked World's Most Sustainable Corporation Sustainable Brands, 2012-01-27, retrieved 2020-04-20^
  12. Corporate Governance and the FTSE4Good Index: A Closer Look^
  13. Clara Stegger. Første danske virksomhed nogensinde: Novo Nordisk rammer gigantisk beløb Finans, 2022-12-02, retrieved 2023-01-18^
  14. Christian Wienberg. Novo's Value Surpasses Denmark GDP After Obesity Drug Boost Bloomberg News, August 9, 2023^
  15. Our history Novo Nordisk Fonden, retrieved 2025-03-13^
  16. Our Heritage Novo Nordisk^
  17. Daniel F. Cuff. BUSINESS PEOPLE; TOP EXECUTIVE NAMED BY NOVO INDUSTRIES The New York Times, 1982-12-16, retrieved 2026-03-14^
  18. A history of... Novo Nordisk pharmaphorum, 2013-02-27, retrieved 2024-11-07^
  19. Jørn Rex. A review of 20 years' experience with the NovoPen family of insulin injection devices Clinical Drug Investigation, 2006^
  20. Our History www.novonordisk.com, retrieved 2019-02-24^
  21. About us - learn more about NNE^
  22. NNIT History www.nnit.com, retrieved 2019-02-24^
  23. Our history www.novozymes.com, retrieved 2023-09-01^
  24. Novo A/S acquires Xellia Pharmaceuticals for US$ 700 million www.businesswire.com, 21 May 2013^
  25. Novo Nordisk transforms vacant building into U.S. headquarters The Star-Ledger, April 18, 2013^
  26. Novo Nordisk Joins Ablynx in Up-to-$399M+ Nanobody® Alliance 25 November 2015^
  27. Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid 8 January 2018^
  28. Novo Nordisk Acquires Ziylo in Possible $800 Million-Plus Deal BioSpace, 17 August 2018^
  29. Henning Mølsted. Dual shift at Novo now testing Corona samples Ingeniøren, 28 March 2020^
  30. Amirah Al Idrus. Novo Nordisk bets $725M on heart-focused Corvidia—with the promise of $1.4B more www.fiercebiotech.com, 2020-06-11, retrieved 2025-05-06^
  31. Novo Nordisk Acquires Emisphere Tech in $1.8 Billion Deal 6 November 2020^
  32. Novo Nordisk Completes Acquisition of Emisphere Technologies for $1.35 Billion 8 December 2020^
  33. Novo Nordisk to Acquire Dicerna 18 November 2021^
  34. Mrinalika Roy, Stine Jacobsen. Novo Nordisk to acquire Forma Therapeutics in $1.1. bln deal Reuters, September 1, 2022^
  35. Eshe Nelson. How Ozempic and Weight Loss Drugs Are Reshaping Denmark's Economy The New York Times, 2023-08-28, retrieved 2023-12-25^
  36. Annika Kim Constantino. Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion CNBC, 2023-08-10, retrieved 2023-08-11^
  37. Novo Bolsters Obesity Pipeline with Potential $500M Embark Biotech Buy 30 August 2023^
  38. Ty Roush. Novo Nordisk Buys Hypertension Drug Ocedurenone For $1.3 Billion—Expanding Ozempic Maker's Arsenal Forbes, 2023-10-16^
  39. Novo Nordisk alleges fraud after $1.3 billion deal to buy hypertension drug from KBP Biosciences Reuters, 18 February 2025^
  40. Paige McNamee. Novo Nordisk seeks US$830m over biotech fraud Capital Brief, 18 February 2025^
  41. Denmark's Novo Nordisk invests €2.1 billion in France Euronews Business, 2023-11-24^
  42. Daniel Gilbert. Novo Nordisk buys manufacturing power as it seeks to ramp up Wegovy The Washington Post, 2024-02-05^
  43. Annika Kim Constantino. Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply CNBC, 2024-02-05^
  44. Karen Gilchrist. Novo Nordisk market cap surpasses Tesla on new obesity pill trial data CNBC, 8 March 2024, retrieved 8 March 2024^
  45. Novartis, Ono Latest to Announce Billion-Dollar M&A Deals 5 March 2024^
  46. Sanne Wass, Naomi Kresge. The Ozempic Effect: How a Weight Loss Wonder Drug Gobbled Up an Entire Economy Bloomberg, April 30, 2024^
  47. Eshe Nelson. How Ozempic Is Transforming a Small Danish Town The New York Times, April 20, 2024^
  48. Eshe Nelson. It Introduced Ozempic to the World. Now It Must Remake Itself. The New York Times, April 20, 2024^
  49. Novo Acquires Majority Stake in Austrian Life Sciences Tools Company 15 May 2024^
  50. Kevin Dunleavy. Novo Nordisk reveals plan to build mammoth $4.1B plant in North Carolina to help produce Ozempic, Wegovy Fierce Pharma, June 24, 2024, retrieved June 26, 2024^
  51. Elsa Ohlen. Novo Nordisk Just Got One Step Closer to Resolving Wegovy Supply Issue barrons, retrieved 2024-12-12^
  52. Oliver Barnes. Can Eli Lilly become the first $1tn drugmaker? Financial Times, October 2, 2024^
  53. Peter Loftus and Dominic Chopping. Novo Nordisk Shares Plummet as Competition Weighs on Sales WSJ, 29 July 2025, retrieved 2025-07-29^
  54. Annika Kim Constantino. Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy CNBC, 2025-03-05, retrieved 2025-04-07^
  55. Novo Nordisk to cuts 9,000 jobs in an effort to streamline its operations - PMLiVE 2025-09-10, retrieved 2025-09-11^
  56. Arundhati Sarkar. Akero Therapeutics soars on $5.2 billion acquisition deal with Novo Nordisk (NVO:NYSE) seekingalpha.com, 2025-10-09, retrieved 2025-10-09^
  57. Annika Kim Constantino. 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market CNBC, 2026-01-10, retrieved 2026-01-28^
  58. Eshe Nelson. Novo Nordisk Tilts G.D.P. In Denmark The New York Times, 2023-08-30, retrieved 2023-10-05^
  59. William B. Mattes. Essential Concepts in Toxicogenomics 2008^
  60. InnoMed PredTox Member Organizations retrieved 2008-08-25^
  61. Innovative Medicines Initiative. IMI Call Topics 2008 IMI-GB-018v2-24042008-CallTopics.pdf, European Commission, retrieved 2008-08-25^
  62. https://www.nytimes.com/2025/11/24/health/ozempic-wegovy-alzheimers-novo-nordisk.html^
  63. Biopharmaceutical Research Unit," Novo Nordisk Corporation novonordisk.com, retrieved 29 November 2011^
  64. Greg Lamm. Novo Nordisk cuts jobs at Seattle research facility bizjournals.com, 4 Sep 2014, retrieved 27 Oct 2014^
  65. Novo Nordisk sheds 400 staff as it refocuses R&D efforts Financial Times, 18 September 2018, retrieved 2 November 2018^
  66. Novo Nordisk Limited, Eli Lilly and Company Limited, Grünenthal Ltd and Napp Pharmaceuticals Limited named in advertisements Prescription Medicines Code of Practice Authority (PMCPA), retrieved 2011-02-07^
  67. Sådan snød Novo Nordisk Skat for 3,6 milliarder retrieved 2013-02-05^
  68. D. Funch, H. Gydesen, K. Tornøe, A. Major-Pedersen, K. A. Chan. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs Diabetes, Obesity and Metabolism, 2014^
  69. Medical alert: Batches of NovoMix 30 FlexPen and Penfill to be recalled Diabetes UK, retrieved 2014-04-25^
  70. David McLaughlin, Andrew M. Harris, Feeley. Novo Nordisk Settles U.S. Suit Over Victoza for $58.65 Million Bloomberg News, 2017-09-06, retrieved 2017-09-06^
  71. Nicola Davis. Firm behind Wegovy slimming jab suspended from UK trade association The Guardian, 2023-03-16^
  72. Natalie Grover. Novo Nordisk suspended from UK lobby group Reuters, 2023-03-16^
  73. RCGP statement on partnership with Novo Nordisk^
  74. Shanti Das, Jon Ungoed-Thomas. 'Skinny jab' drug firm facing fresh inquiries after 'serious breaches' of industry code The Guardian, 2023-03-18^
  75. Diana Novak Jones. Ozempic side effects lawsuit can move forward Reuters, 2023-12-08, retrieved 2026-02-03^
  76. Jenna Greene. Will Ozempic lawsuits be the next big thing in mass litigation? Reuters, 2023-11-22, retrieved 2026-02-03^
  77. Diana Novak Jones. Ozempic side effects lawsuits centralized in Pennsylvania court Reuters, 2024-02-02, retrieved 2026-02-03^
  78. Ian Round. MD man sues Novo Nordisk, alleging Ozempic made him blind The Daily Record, 2025-04-28, retrieved 2026-02-03^
  79. Kevin Dunleavy. Novo Nordisk CEO Jorgensen agrees to testify before Senate over U.S. pricing of semaglutide products Fierce Pharma, June 17, 2024, retrieved June 28, 2024^
  80. President Joe Biden and Sen Bernie Sanders. President Biden: Novo Nordisk, Eli Lilly must stop ripping off Americans with high drug prices USA TODAY, retrieved 2024-07-11^
  81. Annika Kim Constantino. 'Stop ripping us off': Senate grills Novo Nordisk CEO on weight loss drug pricing CNBC, 2024-09-24, retrieved 2024-09-25^
  82. Maker of Ozempic and Wegovy broke advertising rules, regulator finds The Irish Times, retrieved 2025-05-31^
  83. Amanda Bronstad. Judge Strikes Some Claims, Plaintiffs' Experts, in Ozempic Lawsuits Law.com, 2025-08-18, retrieved 2026-02-03^
  84. NOVO NORDISK AKTIE Bilanz GuV finanzen.net, 2025-05-08, retrieved 2025-05-08^
  85. Novo Nordisk - AnnualReports.com www.annualreports.com, retrieved 2025-05-08^
  86. Novo Nordisk A/S Insider Trading & Ownership Structure Simply Wall St, retrieved 2025-05-08^